Targets › IL36R
2 programs from 2 companies in 5 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Sep 2027.
Open in Phaseline: the race on IL36R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| LEO Pharma | Spesolimab IL36 receptor antagonist | IL36R, IL1RAP | Phase 4 | Generalized Pustular Psoriasis; Pyoderma Gangrenosum | Sep 2027 |
| Shanghai Huaota Biopharmaceutical | HB0034 anti-IL-36R monoclonal antibody | IL36R | Phase 2 | Generalized Pustular Psoriasis (GPP); Healthy | – |
Generalized Pustular Psoriasis (2) Pyoderma Gangrenosum (1) Generalized Pustular Psoriasis (GPP) (1) Healthy (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.